Rigor Reviewed

Rigor-Reviewed Manuscript

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Name: Αlpha¹ Rigor Record — Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Item: Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Rating: 59
Author: Αlpha¹

Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O'Brien S, O'Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW, Zoliflodacin Phase 3 Study Group.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2★ (Weak), 0 critical, 6 high issues for “Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsUnsupported claim (uncorroborated)−0.5★
ClaimsOverstated claim−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★
ReportingStatistical analysis partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced8 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions not supported by the paper’s own evidenceAssessed
Conclusions overstated beyond the evidenceAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper reports a well-designed phase 3 trial with a clear scientific premise, robust randomization, and thorough statistical methods. Key reporting gaps include unnamed ethics committees, missing manufacturer details for investigational drugs, imprecise p-value reporting, and internal contradictions in participant counts (South Africa number and trial profile).

Synthesis based on two independent reviewer evaluations (same model, independent runs) that agreed on seven of eight dimensions; the statistical analysis divergence was resolved by weighing the imprecise p-value as a reporting deficiency. Copyedit findings and verification components (citation, statistics, reproducibility, integrity, claim audit) were integrated. The statistics verification covered only 2 tests; the citation check found one reference not located in the registry.

8 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions5 pass · 3 warn

The introduction and Research in context sections cite WHO incidence data, resistance trends, prior failed oral agents (solithromycin, delafloxacin), and ertapenem's limitations. The rationale linking the premise to the trial objective is explicit. The authors acknowledge the absence of a formal literature search before design, and they discuss weaknesses of prior treatments, satisfying the limitations-addressed criterion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific foundation: the global burden of gonorrhoea, antimicrobial resistance concerns, the mechanism and prior phase 1/2 data for zoliflodacin, and the rationale for a phase 3 non-inferiority trial.

Evidence

direct quote[Introduction and Research in context]

“Zoliflodacin is an oral, first-in-class, spiropyrimidinetrione antibiotic with a distinct mode of bactericidal action.”